Current practices in pediatric hospital-acquired thromboembolism: Survey of the Children's Hospital Acquired Thrombosis (CHAT) Consortium.
anticoagulants
hospital
pediatric
risk assessment
risk factors
venous thromboembolism
Journal
Research and practice in thrombosis and haemostasis
ISSN: 2475-0379
Titre abrégé: Res Pract Thromb Haemost
Pays: United States
ID NLM: 101703775
Informations de publication
Date de publication:
Oct 2022
Oct 2022
Historique:
received:
20
04
2022
accepted:
03
08
2022
medline:
29
11
2023
pubmed:
29
11
2023
entrez:
29
11
2023
Statut:
epublish
Résumé
A rise in hospital-acquired venous thromboembolism (HA-VTE) in children has led to increased awareness regarding VTE prophylaxis and risk assessment. Despite no consensus exists regarding these practices in pediatrics. To describe common practices in VTE prophylaxis, VTE risk assessment models, and anticoagulation dosing strategies in pediatric hospitals that are members of the Children's Hospital Acquired Thrombosis (CHAT) Consortium. An electronic survey of 44 questions evaluating practices surrounding pediatric HA-VTE risk assessment and prevention was distributed between August 9, 2021, and August 30, 2021, to the primary investigators from the 32 institutions within the CHAT Consortium. The survey response rate was 100% ( Practices among institutions are variable in regard to use of HA-VTE prophylaxis, risk assessment, or guideline implementation, highlighting the need for further research and a validated risk assessment model through groups like the CHAT Consortium.
Sections du résumé
Background
UNASSIGNED
A rise in hospital-acquired venous thromboembolism (HA-VTE) in children has led to increased awareness regarding VTE prophylaxis and risk assessment. Despite no consensus exists regarding these practices in pediatrics.
Objective
UNASSIGNED
To describe common practices in VTE prophylaxis, VTE risk assessment models, and anticoagulation dosing strategies in pediatric hospitals that are members of the Children's Hospital Acquired Thrombosis (CHAT) Consortium.
Methods
UNASSIGNED
An electronic survey of 44 questions evaluating practices surrounding pediatric HA-VTE risk assessment and prevention was distributed between August 9, 2021, and August 30, 2021, to the primary investigators from the 32 institutions within the CHAT Consortium.
Results
UNASSIGNED
The survey response rate was 100% (
Conclusion
UNASSIGNED
Practices among institutions are variable in regard to use of HA-VTE prophylaxis, risk assessment, or guideline implementation, highlighting the need for further research and a validated risk assessment model through groups like the CHAT Consortium.
Identifiants
pubmed: 38024326
doi: 10.1002/rth2.12793
pii: S2475-0379(22)02441-4
pmc: PMC10656282
doi:
Types de publication
Journal Article
Langues
eng
Pagination
e12793Informations de copyright
© 2022 The Authors. Research and Practice in Thrombosis and Haemostasis published by Wiley Periodicals LLC on behalf of International Society on Thrombosis and Haemostasis (ISTH).
Références
J Thromb Haemost. 2021 Feb;19(2):522-530
pubmed: 33305475
N Engl J Med. 2021 Aug 26;385(9):790-802
pubmed: 34351721
Chest. 2012 Feb;141(2 Suppl):e195S-e226S
pubmed: 22315261
J Pediatr. 1996 Mar;128(3):313-8
pubmed: 8774496
J Thromb Haemost. 2017 Nov;15(11):2274-2278
pubmed: 29027741
Pediatr Crit Care Med. 2022 Jan 1;23(1):e1-e9
pubmed: 34406168
Pediatrics. 2009 Oct;124(4):1001-8
pubmed: 19736261
Ann Thorac Surg. 2018 Aug;106(2):404-411
pubmed: 29626461
Front Pediatr. 2017 Sep 19;5:198
pubmed: 28975127
Nurs Res. 2002 Nov-Dec;51(6):398-403
pubmed: 12464760
J Thromb Haemost. 2012 Jul;10(7):1326-34
pubmed: 22583578
JAMA. 2021 Apr 27;325(16):1620-1630
pubmed: 33734299
Thromb Res. 2003 Jan 25;109(2-3):85-92
pubmed: 12706636
J Intensive Care Med. 2011 Sep-Oct;26(5):314-7
pubmed: 21436172
Thromb Res. 2018 Jan;161:67-72
pubmed: 29207321
J Pediatr. 2014 Feb;164(2):332-8
pubmed: 24332452
J Pediatr. 2021 Jan;228:252-259.e1
pubmed: 32920105
Ann Pharmacother. 2018 Sep;52(9):898-909
pubmed: 29592538
Front Pediatr. 2017 Apr 10;5:68
pubmed: 28443269
Pediatr Blood Cancer. 2021 Jul;68(7):e28975
pubmed: 33661561
Blood. 2021 Jul 15;138(2):190-198
pubmed: 33895804
Thromb Res. 2019 Apr;176:1-7
pubmed: 30743065
Am J Surg. 2017 Jun;213(6):1143-1152
pubmed: 27692434
BMJ. 2021 Oct 14;375:n2400
pubmed: 34649864
Pediatr Blood Cancer. 2017 Jul;64(7):
pubmed: 27905682
Blood Adv. 2021 Feb 9;5(3):872-888
pubmed: 33560401
J Thromb Thrombolysis. 2021 Jul;52(1):209-213
pubmed: 33486673
Pediatrics. 2022 Mar 1;149(3):
pubmed: 35156127
Chest. 2022 Jul;162(1):213-225
pubmed: 35167861
JAMA Intern Med. 2021 Dec 1;181(12):1612-1620
pubmed: 34617959
Pediatr Blood Cancer. 2021 Jul;68(7):e29049
pubmed: 33955167
Chest. 2020 Sep;158(3):1143-1163
pubmed: 32502594
Chest. 2012 Feb;141(2 Suppl):e737S-e801S
pubmed: 22315277
Int J Surg Case Rep. 2016;28:114-116
pubmed: 27693871
J Thromb Haemost. 2020 Nov;18(11):3099-3105
pubmed: 33174388
Front Pediatr. 2017 Jan 26;5:9
pubmed: 28184368
Pediatr Blood Cancer. 2009 Dec;53(6):960-6
pubmed: 19544387
Pediatrics. 2021 Jun;147(6):
pubmed: 34011634
Pediatrics. 2022 Jul 1;150(1):
pubmed: 35484817
Thromb Res. 2021 Sep;205:92-98
pubmed: 34293539
J Pediatr Hematol Oncol. 2016 May;38(4):301-7
pubmed: 26925711